Skip to main content
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. — Investor Relations & Filings

Ticker · AQST ISIN · US03843E1047 US Manufacturing
Open in API
Filings indexed 607 across all filing types
Latest filing 2026-04-24 Annual Report
Country US United States of America
Listing US AQST

About Aquestive Therapeutics, Inc.

https://aquestive.com/

Aquestive Therapeutics is a pharmaceutical company that develops and commercializes medicines using its proprietary PharmFilm® technology. This oral film drug delivery system provides a non-invasive and convenient alternative to conventional therapies, such as injections, by enabling the oral administration of complex molecules. The company's development pipeline is focused on addressing unmet medical needs in central nervous system (CNS) disorders and severe allergic reactions. Key product candidates include Anaphylm™, an epinephrine sublingual film for the emergency treatment of anaphylaxis, and Libervant®, a diazepam buccal film for the management of seizure clusters.

Recent filings

Filing Released Lang Actions
ARS - Aquestive Therapeutics, Inc. (0001398733) (Filer)
Annual Report
2026-04-24 English
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of a Type A meeting with the FDA regarding the resubmission of a New Drug Application (NDA) for a pharmaceutical product. It contains detailed information about regulatory feedback, study designs, and future plans for the NDA resubmission. The document is not a full regulatory filing or report but rather an update on regulatory progress and company guidance. It does not contain financial statements or detailed financial analysis, nor is it a transcript, management report, or other specific report type. It is a regulatory announcement related to FDA interactions and drug development progress, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2026-03-30 English
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
Board/Management Information Classification · 95% confidence The document is a press release announcing leadership changes at Aquestive Therapeutics, specifically the appointment of a new Chief Legal Officer and Chief Compliance Officer, and the change in roles of an existing executive. It includes details about the new appointee's background, the equity inducement grant under Nasdaq rules, and forward-looking statements. There are no financial statements, earnings data, or detailed financial analysis present. The content focuses on management changes and related corporate governance matters. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (9259 characters) supports that it is a full announcement rather than a brief note or a report publication announcement.
2026-03-20 English
8-K - AQUESTIVE THERAPEUTICS, INC. (0001398733) (Filer)
Investor Presentation Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated February 26, 2026. It specifically states in Item 7.01 that it is furnishing information in the form of an investor presentation to be given at meetings with institutional investors and analysts. The document includes a corporate presentation as Exhibit 99.1 and mentions that the presentation is available on the company's website. There are no financial statements or detailed financial data included in the text, only a reference to the presentation. The document length is 4168 characters, which is relatively short and consistent with an announcement or filing of a presentation rather than a full report. According to the classification rules, this type of document is best classified as an Investor Presentation (IP).
2026-02-26 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 2, 2026. It reports a recent event: the receipt of a Complete Response Letter (CRL) from the FDA regarding a New Drug Application. It also includes a press release and an investor presentation as exhibits. The content is primarily an announcement of a regulatory event and related disclosures, not a full financial report or detailed financial statements. The document length is about 5,325 characters, which is relatively short and consistent with a current report. There is no detailed financial data or comprehensive analysis typical of Annual Reports (10-K), Interim Reports (IR), or Earnings Releases (ER). The document also includes an investor presentation but the main filing is the Form 8-K itself, which is a regulatory filing used to announce material events. Therefore, the best classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2026-02-02 English
S-8 Filing
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Aquestive Therapeutics, Inc. It registers additional shares of common stock under the company's 2018 Equity Incentive Plan. The document includes incorporation by reference of prior filings such as Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, but itself is a registration statement for securities issuance under an equity incentive plan. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication announcement, but a full registration statement filing.
2026-01-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.